Clinical Trial Detail

A Study of Zanubrutinib (BGB-3111) in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment With Ibrutinib

Complete title: A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib

Research Study Number	10262
Principal Investigator	Mazyar Shadman
Phase	II

Look up trial at NIH

Research Study Description

To evaluate the safety of zanubrutinib (also known as BGB-3111) in participants with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior ibrutinib treatment as defined per protocol as measured by frequency and severity of adverse events

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above **

Other eligibility criteria may apply.

Research Study Number

10262

Keywords: Leukemia, Chronic Lymphocytic (CLL)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed

Last Modified, June 25, 2019